NCT03314740View on ClinicalTrials.gov

Best Approach in Recurrent-Ovarian-Cancer-with Cediranib-Olaparib

PHASE2CompletedINTERVENTIONAL
Enrollment

123

Participants

Timeline

Start Date

June 12, 2017

Primary Completion Date

April 1, 2021

Study Completion Date

April 1, 2021

Conditions
Ovarian Neoplasms
Interventions
DRUG

Paclitaxel

Comparator active compound

DRUG

Cediranib

Experimental compound

DRUG

Olaparib

Experimental compound

Trial Locations (6)

20141

Istituto Eurpeo di Oncologia (IEO), Milan

20900

Ospedale San Gerardo - ASST Monza, Monza

25123

Spedali Civili di Brescia, Brescia

35128

Istituto Oncologico Veneto (IOV), Padua

42123

Arcispedale Santa Maria Nuova, Reggio Emilia

00161

Policlinico Umberto I - Università La Sapienza, Rome

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Mario Negri Institute for Pharmacological Research

OTHER